drugset
drugset / Trial / NCT06698016

A Study of the Effect of Efavirenz on the Plasma Levels of Nemtabrutinib (MK-1026-014)

NCT06698016 ↗

Phase 1 Completed 16 enrolled Merck Sharp & Dohme LLC
Non-randomizedSequentialOpen-labelBasic science

Summary

The goal of the study is to learn what happens to levels of nemtabrutinib (MK-1026) in a healthy person's body over time. Researchers will compare what happens to nemtabrutinib in the body when it is given with or without another medicine called efavirenz.

Timeline

Start
2023-07-25
Primary completion
2023-10-30
Completion
2023-10-30

Drugs

EvaluationDrugModalityDoseRoute
Subject Efavirenz Other / unclassified — Oral
Subject Nemtabrutinib Other / unclassified — Oral

Indications

No indication recorded.